Company Research Report
Company Overview
Name, Mission of the Company
- Name: Cellares
- Mission: Accelerating Access to Life-Saving Cell Therapies
When was the Company Founded and by Whom
No information is available
Key People in the Company
- Fabian Gerlinghaus: Co-Founder & CEO
- Omar Kurdi: Co-Founder & President
- Gary Lo: Chief Financial Officer
- Arturo Araya: EVP of Commercialization
- Antinea Chair: VP of Technical Operations
- Meredith Daviou: VP of Finance
- Joe Ferrary: VP of Quality Operations
- Eric Fulmer: VP of Quality
- Daniele Malleo: VP of Research and Development
- John Tomtishen: SVP of Operations
- Wilson Toy: VP of Technology
Board of Advisors
- Carl June: Professor in Immunotherapy, University of Pennsylvania
- Christi Shaw: Former CEO, Kite Pharma
- Megan (Suhoski) Davis, PhD: Director, PDL University of Pennsylvania
- Timothy Moore: CTO, Allogene Therapeutics
- Rod Rietze, PhD: Co-Founder & CEO, iVexSol
- Ezekiel J. Emanuel: Vice Provost Global Initiatives, University of Pennsylvania
Board of Directors
- Fabian Gerlinghaus: Co-Founder & CEO
- Omar Kurdi: Co-Founder & President
- Justin Butler: Partner, Eclipse Partners
- Victor Tong: Managing Director, Decheng Capital
- David Mauney: Managing Director, Koch Disruptive Technologies
Location
- Headquarters: 345 Allerton Ave, South San Francisco, CA 94080
Number of Employees
No information is available
Revenue of the Company
No information is available
Company Recognition
- Cellares is known for being the first Integrated Development and Manufacturing Organization (IDMO) with a strong emphasis on fully automated and scalable cell therapy manufacturing solutions.
Products
What Products Do They Offer
1. Cell Shuttleᵀᴹ
2. Cell Qᵀᴹ
High-Level Description of the Products
- Cell Shuttleᵀᴹ: A modular, cGMP platform designed for industrial scale cell therapy manufacturing.
- Cell Qᵀᴹ: The world’s first automated cGMP quality control (QC) workcell for cell therapies.
Key Features of Each Product
Cell Shuttleᵀᴹ
- Scalability: Can process up to 16 batches in parallel.
- Quality Improvement: 75% fewer process failures and 90% less labor required.
- Cost Efficiency: Up to 50% reduction in batch price.
- Flexibility: Majority of cell therapy modalities supported.
- High Throughput: 10x increase in productivity.
Cell Qᵀᴹ
- High Throughput QC: Automates the testing of up to 6,000 batches per year.
- Cost Efficiency: Up to 50% lower price per batch.
- Integrated Automation: Complements Cell Shuttleᵀᴹ for a fully end-to-end automated solution.
- Flexibility: Modular platform that can incorporate new instruments, enabling customization.
Recent Developments
What Are the Recent Developments in the Company
1. April 22, 2024: Bristol Myers Squibb and Cellares announce a $380M worldwide capacity reservation and supply agreement for the manufacture of CAR T cell therapies. This partnership involves the deployment of Cell Shuttles and Cell Q systems across Cellares’ IDMO Smart Factories in the U.S., EU, and Japan.
2. April 18, 2024: Cellares launches Cell Q, an automated cGMP QC workcell for cell therapies designed to resolve manual QC processing bottlenecks and extend IDMO capabilities from manufacturing through quality control.
3. June 27, 2024: Agreement with Kite to evaluate Cellares’ Cell Shuttle Automated Manufacturing Platform.
What Are the New Products Launched
- Cell Qᵀᴹ: Launched on April 18, 2024, it is the first automated cGMP QC workcell for cell therapies.
What Are the New Features Added to the Existing Products
No information is available
Any New Partnerships
- Kite, a Gilead Company: Agreement to evaluate Cellares’ automated manufacturing platform, the Cell Shuttle, announced on June 27, 2024.
- Bristol Myers Squibb: Worldwide capacity reservation and supply agreement for the manufacture of CAR T cell therapies announced on April 22, 2024.
